Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- PMDA to Increase Its Number of GMP Inspectors, Biostatisticians
December 6, 2004
- Nikken Chemicals: Profits Up Sharply Despite Decline in Sales
December 6, 2004
- US, EU, Nippon Keidanren Present Requests on Regulatory Reform
December 6, 2004
- Teikoku Hormone: Pharma, Animal Health Segments Post Lower Sales
December 6, 2004
- REGULATORY NEWS IN BRIEF
December 6, 2004
- Wakamoto: Ethical Drug Div. Posts Declines in Sales, Profits
December 6, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 6, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 6, 2004
- Rohto: Sales Up 6.3% at \32,207 Mil.
December 6, 2004
- Tanabe to License out Its Compounds after PIIa
December 6, 2004
- Dainippon, Sumitomo Pharm to Merge Oct. 1, 2005
December 6, 2004
- Sawai: Flat Sales, Sharp Decline in Profits
December 6, 2004
- Tsumura to Begin Clinical Trial of Kampo Drug from PII in US
December 6, 2004
- Increasing Number of Foreign Companies Aim at Japanese Market
December 6, 2004
- Competition Between Original Drugs and Generics to Intensify: Mr Sawai
December 6, 2004
- Japan's 1st Treatment GL on Ovarian Cancer Published: JSGO
December 6, 2004
- JPMA to Present Proposals on NHI Price System Next Year
December 6, 2004
- Nichiban: Strong Increase in Profits Despite Flat Sales
December 6, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 6, 2004
- FJPWA SEMINAR
December 6, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…